APLS240719C45000
- 0.15
- -0.03-16.67%
Apellis Pharmaceuticals Newsroom
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Apellis Pharmaceuticals’ (APLS Quick QuoteAPLS - Free Report) marketed portfolio comprises two drugs — Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection).
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $49
Mizuho Securities analyst Graig Suvannavejh maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $52 to $49.According to TipRanks data, the analyst has a
Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $49 From $52
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $82
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
Apellis Pharmaceuticals Price Target Maintained With a $100.00/Share by Baird
Apellis Pharmaceuticals Price Target Maintained With a $100.00/Share by Baird
Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.
Apellis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 161.16% Baird $100 → $100 Maintains Outperform 05/31/2024 20.13% Piper Sandler → $46 Initiates
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Baird analyst Colleen M. Kusy maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 28.9% and a total average return of -11.8% ov
Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geogr
Apellis Falls as EU Experts Decline to Back Eye Disorder Therapy
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
J.P. Morgan analyst Anupam Rama maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.6% and a total average return of 4.6% ov
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $48
Wells Fargo analyst Derek Archila maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 4
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $40 From $50, Maintains Neutral Rating
Apellis Pharmaceuticals (APLS) has an average outperform rating and a price target range of $46 to $111, according to analysts polled by Capital IQ. Price: 39.78, Change: -1.74, Percent Change: -4.19
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.2% on Friday.Shares of NIKE, Inc. (NYSE:NKE) fell sharply in today's pre-market trading following fourth-quarter e
Apellis Pharmaceuticals's Geographic Atrophy Treatment Gets Negative Opinion in EU
By Michael Susin Apellis Pharmaceuticals said the marketing authorization application of its geographic atrophy treatment received a negative opinion from the European Medicines Agency's Committee fo
Express News | Apellis Pharmaceuticals Inc - Plans to Seek Re-Examination and Expects a Final Opinion in Q4 of 2024
Express News | Apellis Plans to Seek Re-Examination Following Negative Chmp Opinion for Pegcetacoplan for Geographic Atrophy (Ga) in the EU
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine
Apellis Pharmaceuticals Insider Sold Shares Worth $1,451,835, According to a Recent SEC Filing
A. Sinclair Dunlop, Director, on June 21, 2024, sold 37,000 shares in Apellis Pharmaceuticals (APLS) for $1,451,835. Following the Form 4 filing with the SEC, Dunlop has control over a total of 302,37